Roche Inks Up To $1.39B Deal For Goodwin-Advised Biotech
Law360 (November 15, 2019, 11:52 AM EST) -- Swiss health care giant Roche AG has inked an agreement potentially worth up to $1.39 billion to buy Goodwin Procter-advised Promedior Inc., a privately backed biotech focused on developing treatments for fibrosis, the companies said Friday.
The transaction adds to Roche's portfolio a venture capital-backed biotech in Promedior that is based in Lexington, Massachusetts and has multiple treatments for fibrotic diseases in development, according to a statement. Promedior's candidates to treat such diseases are based on Pentraxin-2, an endogenous human protein that works as an agonist to initiate a process to prevent and potentially reverse fibrosis. Agonists are chemicals that bind to a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!